Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Tumor-associated macrophages (TAMs) have multiple potent functions in cancer and, thus,
represent important therapeutic targets. These diverse functions highlight the heterogenous …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Circulating tumor cells (CTCs), shed by primary malignancies, function as" seeds" for distant
metastasis. However, it is still largely unknown how CTCs escape immune surveillance …

Each tumour contains diverse cellular states that underlie intratumour heterogeneity (ITH), a
central challenge of cancer therapeutics. Dozens of recent studies have begun to describe …

Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

The aryl hydrocarbon receptor (AhR) is a sensor of products of tryptophan metabolism and a
potent modulator of immunity. Here, we examined the impact of AhR in tumor-associated …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Severe immune-related adverse events (irAEs) occur in up to 60% of patients with
melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …